Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2020-12-21 08:00 3944

Antengene Announces Approval of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2020-12-18 15:34 5587

Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

SHANGHAI and HONG KONG, Dec. 11, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2020-12-11 08:00 5068

Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology

SHANGHAI and HONG KONG, Dec. 9, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2020-12-09 08:00 3526

Antengene Announces Acceptance of IND Application in China for ATG-010 (selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

SHANGHAI and HONG KONG, Dec. 7, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2020-12-07 08:00 3664

Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

SHANGHAI and HONG KONG, Dec. 3, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2020-12-03 20:00 5857

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", H...

2020-11-26 14:04 5821

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", H...

2020-11-26 10:32 5190

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Nov. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK)...

2020-11-20 21:09 13016

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

SHANGHAI, Oct. 10, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceuti...

2020-10-15 08:59 2760

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

Antengene's New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer

SHANGHAI, Oct. 12, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceutic...

2020-10-12 20:00 4976

Antengene's New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer

Australian Therapeutic Goods Administration Approves the First Phase I Trial of ATG-017 for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies

SHANGHAI and MELBOURNE, Australia, Aug. 13, 2020 /PRNewswire/ -- Antengene Corporation, a leading i...

2020-08-13 06:00 2575

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

SHANGHAI, July 20, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative hematology and ...

2020-07-20 08:00 9285

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

Antengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development

SHANGHAI and MELBOURNE, Australia, July 13, 2020 /PRNewswire/ -- Antengene Corporation (Antengene) ...

2020-07-13 06:00 4623

Antengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development

Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

SHANGHAI and PHILADELPHIA, July 1, 2020 /PRNewswire/ --Antengene Corporation today announced its a...

2020-07-02 08:16 1557

Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

SHANGHAI and HONG KONG, June 8, 2020 /PRNewswire/ -- Antengene Corporation (Antengene) today announ...

2020-06-08 20:00 2236

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets

SHANGHAI, May 5, 2020 /PRNewswire/ -- Antengene Corporation (Antengene) today announced a broaden...

2020-05-05 20:30 1995

Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin's Lymphoma

SHANGHAI and PHILADELPHIA, April 14, 2020 /PRNewswire/ -- Antengene announced today that it has dos...

2020-04-14 21:15 1484

Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions

SHANGHAI and MELBOURNE, Australia, April 13, 2020 /PRNewswire/ -- Antengene Corporation today annou...

2020-04-13 20:00 3346

Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions

Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors

SHANGHAI and PHILADELPHIA, Jan. 8, 2020 /PRNewswire/ -- The Antengene board today announced the app...

2020-01-08 20:00 3184